AU2002210925A1 - Preventives/remedies for portal hypertension - Google Patents
Preventives/remedies for portal hypertensionInfo
- Publication number
- AU2002210925A1 AU2002210925A1 AU2002210925A AU1092502A AU2002210925A1 AU 2002210925 A1 AU2002210925 A1 AU 2002210925A1 AU 2002210925 A AU2002210925 A AU 2002210925A AU 1092502 A AU1092502 A AU 1092502A AU 2002210925 A1 AU2002210925 A1 AU 2002210925A1
- Authority
- AU
- Australia
- Prior art keywords
- preventives
- remedies
- portal hypertension
- portal
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000007232 portal hypertension Diseases 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-326131 | 2000-10-25 | ||
| JP2000326131 | 2000-10-25 | ||
| PCT/JP2001/009311 WO2002034263A1 (en) | 2000-10-25 | 2001-10-24 | Preventives/remedies for portal hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002210925A1 true AU2002210925A1 (en) | 2002-05-06 |
Family
ID=18803372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002210925A Abandoned AU2002210925A1 (en) | 2000-10-25 | 2001-10-24 | Preventives/remedies for portal hypertension |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040102502A1 (en) |
| EP (1) | EP1329218A4 (en) |
| AU (1) | AU2002210925A1 (en) |
| CA (1) | CA2426674A1 (en) |
| WO (1) | WO2002034263A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032854A1 (en) * | 2001-12-03 | 2005-02-10 | Kiminori Kawahara | Insulin resistance improving agents |
| JP2006516020A (en) * | 2002-08-28 | 2006-06-15 | キュリス インコーポレイテッド | Co-administration of morphogens and ACE inhibitors in the treatment of chronic renal failure |
| DE10325813B4 (en) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxis and / or therapy in portal hypertension |
| RU2007101509A (en) * | 2004-06-17 | 2008-07-27 | Уайт (Us) | METHOD FOR PRODUCING HORMONE RECEPTOR ANTAGONISTS RELEASING GONADOTROPINE |
| EP1758895A1 (en) | 2004-06-17 | 2007-03-07 | Wyeth a Corporation of the State of Delaware | Gonadotropin releasing hormone receptor antagonists |
| WO2006058012A2 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US7531542B2 (en) * | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| TWI414310B (en) * | 2006-12-26 | 2013-11-11 | Daiichi Sankyo Co Ltd | Elution-improved pharmaceutical preparation |
| TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
| TW201006823A (en) * | 2008-07-14 | 2010-02-16 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| GB201321738D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| JPH05112533A (en) * | 1991-05-08 | 1993-05-07 | Upjohn Co:The | Imidazobenzoquinoline and agent for preventing and treating hypertension and conjestive heart failure containing same as effective component |
| NO304429B1 (en) * | 1992-12-17 | 1998-12-14 | Sankyo Co | Biphenyl derivatives, pharmaceutical preparations and their use in the manufacture of a medicament for the treatment of hypertension and heart disease |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| EP0855392A3 (en) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Five-membered heterocycles having biphenylsulphonyl substituents, processes for the preparation thereof, their use as medicaments or diagnostic agent and medicaments containing them |
| DE69914460T2 (en) * | 1998-03-04 | 2004-10-28 | Takeda Chemical Industries, Ltd. | PREPARATION WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES FOR AII ANTAGONISTS, THEIR PRODUCTION AND USE |
| US6638937B2 (en) * | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| EP1140041A2 (en) * | 1999-01-05 | 2001-10-10 | University of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6211217B1 (en) * | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| AU3408801A (en) * | 2000-02-18 | 2001-08-27 | Takeda Chemical Industries Ltd | Tnf-alpha inhibitors |
| JP2001302512A (en) * | 2000-02-18 | 2001-10-31 | Takeda Chem Ind Ltd | Tnf-alpha inhibitor |
| JP2001316296A (en) * | 2000-02-21 | 2001-11-13 | Takeda Chem Ind Ltd | Controlled release preparation for biologically active compound having poor solubility to water, method for producing the same and use thereof |
| AU2001232348A1 (en) * | 2000-02-21 | 2001-08-27 | Takeda Chemical Industries Ltd. | Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same |
| US20030119010A1 (en) * | 2001-03-01 | 2003-06-26 | University Of Queensland | Polynucleotides and polypeptides linked to a disease or condition |
-
2001
- 2001-10-24 WO PCT/JP2001/009311 patent/WO2002034263A1/en not_active Ceased
- 2001-10-24 CA CA002426674A patent/CA2426674A1/en not_active Abandoned
- 2001-10-24 EP EP01978864A patent/EP1329218A4/en not_active Withdrawn
- 2001-10-24 AU AU2002210925A patent/AU2002210925A1/en not_active Abandoned
- 2001-10-24 US US10/415,130 patent/US20040102502A1/en not_active Abandoned
-
2006
- 2006-03-29 US US11/391,208 patent/US20060173059A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1329218A4 (en) | 2007-04-04 |
| EP1329218A1 (en) | 2003-07-23 |
| WO2002034263A1 (en) | 2002-05-02 |
| US20040102502A1 (en) | 2004-05-27 |
| US20060173059A1 (en) | 2006-08-03 |
| CA2426674A1 (en) | 2002-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001234128A1 (en) | Novel imidazoline compounds | |
| AU2001246876A1 (en) | Remedies | |
| AU2001258771A1 (en) | -secretase inhibitors | |
| AU2001246877A1 (en) | Remedies | |
| AU2002210925A1 (en) | Preventives/remedies for portal hypertension | |
| AU2001252599A1 (en) | Remedies for cancer | |
| AU2001266345A1 (en) | Five-membered-ring compound | |
| AU2001277711A1 (en) | Remedies for cisplatin-tolerant cancer | |
| AU2001220281A1 (en) | Rollerboard for road-skiing | |
| AU3987800A (en) | Preventives/remedies for angiostenosis | |
| AU2001232271A1 (en) | Preventives/remedies for postoperative stress | |
| AU2002222676A1 (en) | Preventives or remedies for endometriosis | |
| AU2002367106A1 (en) | Remedies for mild recognition deflict | |
| AU2001275043A1 (en) | Mineral supplement | |
| AU2002359916A1 (en) | Preventives/remedies for cancer | |
| AU2003236039A1 (en) | Preventives/remedies for hotflash | |
| AU2001295952A1 (en) | Novel remedies or preventives for angiostenosis | |
| AU2001252578A1 (en) | Preventives for influenza | |
| AU2002214681A1 (en) | Hypertension | |
| AU2001232258A1 (en) | Remedies for degenerative arthritis | |
| AU2002233208A1 (en) | Prismatic joint | |
| AU5070901A (en) | Method for demercaptanizing hydrocarbon stock | |
| AU2001276480A1 (en) | Joint forming tool | |
| AU2001264286A1 (en) | Preventives/remedies for granuloma | |
| AU2002361102A1 (en) | Preventives/remedies for cancer |